TPCN2 and cancer: Carriage of TPCN2 rs3750965:GG was associated with a lower general risk of developing cancer (odds ratio (OR): 0.97, 95% confidence interval (CI): 0.95–0.997, P = 0.029*, vs. A/A), whereas carriage of TPCN2 rs35264875:TA and rs72932540:GA was associated with an increased risk of cancer susceptibility (OR: 1.03, 95% CI: 1.01–1.05, P = 0.001**, vs. A/A and OR: 1.07, 95% CI: 1.05–1.09, P = 4.51e−10***, vs. A/A, respectively) (see Table 2 and Fig. 2a).